natera™ | Signatera™
Residual disease test (MRD)

For those who have been diagnosed with stage II–III colorectal cancer

Discussion guide for the Signatera™ residual disease test

Signatera is a new custom-built test that uses tumor and blood samples to detect very low levels of molecular residual disease (MRD), or small traces of cancer, allowing you and your doctor access to more information, sooner. Use this discussion guide along with the patient brochure to help make the most of your next conversation about Signatera with your doctor.

Key information about Signatera

- Clinically shown to accurately detect MRD over time[1]
- Medicare draft coverage[2]
- Convenient blood draw services either in clinics or at home

Requirements and timing

- Both tissue and blood samples are required initially to build the Signatera test. Once the test is built, only blood samples are required for the periodic follow-up tests performed to monitor for MRD.
- After your test has been designed (approximately three weeks), your doctor should receive your results approximately one week after your blood sample is received by the lab.

Questions to ask your doctor:

- What is the difference between Signatera and other cancer monitoring tools, such as CEA blood test and CT scans?
- How often do I need to be tested with Signatera?
- What do negative and positive Signatera results mean?
- During treatment, how will each follow-up test result show if the treatment is working?
- After treatment, how long should we continue to monitor the disease?

1. Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. *JAMA Oncol. 2019*;5(8):1124–1131.
2. Medicare coverage is in process for Signatera. Coverage will become available for patients with stage II–III colon cancer and stage IIA rectal cancer during the MRD setting and for patients with stage II–III colorectal cancer during the surveillance setting.

Notes for your discussion:

My care plan includes these tests:

These tests were chosen because

The results from these tests will tell me

I still have questions about

For more information about Signatera, contact our Patient Coordinators at **650.489.9050** or **Signaterapc@natera.com**

natera™

Do you want to speak to somebody with more information outside of your careteam?

Advocacy groups are great resources for providing additional information for patients, caregivers, and survivors on many topics including treatments, testing, clinical trials and studies, survivorship, and nutrition.

Here are some recommended colorectal cancer-focused organizations:

colorectal cancer alliance

877.422.2030

FIGHT COLORECTAL CANCER

877.427.2111

COLONTOWN A PALTOWN COMMUNITY

colontown.org

201 Industrial Road, Suite 410
San Carlos, CA 94070
natera.com/signatera
1.650.489.9050 | Fax 1.650.412.1962